SEATTLE, Nov. 25 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that management will present at the following two investor conferences next month. NASDAQ OMX 23rd Investor Program, London Tuesday, December 1, 2009 4:30 a.m. ET 2009 Deutsche Bank Biotech Boston Confab Tuesday, December 15, 2009 10:00 a.m. ET The presentations will be audio webcast live and available for replay from Dendreon's website, http://www.dendreon.com/. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. DATASOURCE: Dendreon Corporation CONTACT: Katherine Stueland, V.P. Corporate Communications & Investor Relations of Dendreon Corporation, +1-206-829-1522 Web Site: http://www.dendreon.com/

Copyright